Risultati per: Test delle urine per la diagnosi di cancro

Efficace in fase iniziale, con un’accuratezza fino al 98%

Stroke, Ahead of Print. Right-to-left shunt, mainly due to patent foramen ovale (PFO), is likely responsible for ≈5% of all ischemic strokes and 10% of those occurring in young and middle-aged adults. Randomized clinical trials demonstrated that, in selected young and middle-aged patients with otherwise cryptogenic acute ischemic stroke and high-risk PFO, percutaneous PFO closure is more effective than antiplatelet therapy alone in preventing recurrence. However, PFO is generally a benign finding and is present in about one-quarter of the population. Therefore, in clinical practice, identifying PFOs that are likely to be pathogenetic is crucial for selecting suitable patients for PFO closure to prevent recurrent stroke and to avoid potentially harmful and costly overtreatment. Contrast transthoracic echocardiography has a relatively low sensitivity in detecting PFO, whereas transesophageal echocardiography is currently considered the gold standard for PFO detection. However, it is a relatively invasive procedure and may not always be easily feasible in the subacute setting. Contrast transcranial Doppler is a noninvasive, inexpensive, accurate tool for the detection of right-to-left shunt. We conducted a literature review on the use of contrast transcranial Doppler to detect and grade right-to-left shunt after an acute ischemic stroke and present a clinical workflow proposal for young and middle-aged patients.

When this scenario occurs during screening, incidence of upper endoscopy–detectable cancer is very low.

Anderloni (Aigo): “Contano gli stili di vita e diagnosi precoce”

Anderloni (Aigo): “Contano gli stili di vita e diagnosi precoce”

Caressa e Bergomi, in ogni campo fondamentale gioco di squadra

Fnopi, “aumentare l’attrattività con formazione e retribuzioni”

Lo ribadisce il più grande studio condotto, incaricato dall’Oms

Annals of Internal Medicine, Volume 177, Issue 9, Page JC107, September 2024.

Annals of Internal Medicine, Ahead of Print.

In July, the World Health Organization (WHO) prequalified the first hepatitis C virus (HCV) self-test. The product, called OraQuick HCV self-test, is an extension of the OraQuick HCV Rapid Antibody test that the agency prequalified in 2017 for professional use. This self-test kit is designed as a convenient and stigma-free way to reach people who might not otherwise get tested for HCV and therefore go undiagnosed.

Capace di rilevare da foto del cervello le alterazioni genetiche

Conferita all’Azienda Ospedaliero Universitaria delle Marche

Oms chiede una procedura di emergenza, ‘urge accesso più rapido’